AR and neoplasm: Consistent with our prior results, we observed that mice vaccinated with Ad-AR-V7 with the addition of anti-PD1 had significantly more AR-specific responses in IFNγ ELISpot assays on splenocytes collected at humane endpoints or 66 days post-tumor-implantation (Figure S7).